Protein Engineering, Vol. 14, No. 12, 1035-1041,
December 2001
© 2001 Oxford University Press
Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion
1 Fenske Laboratory, University Park, PA 16802, 2 Section on Biophysical Chemistry, Laboratory of Molecular Biology, National Institute of Mental Health, Bethesda, MD 28092-4034, 3 Novartis Pharmaceuticals, Summit, NJ 07901 and 5 Division of Transplantation Immunology, University of Alabama at Birmingham, AL 35294, USA
Anti-CD3 immunotoxins exhibit considerable promise for the induction of transplantation tolerance in pre-clinical large animal models. Recently an anti-human anti-CD3
single-chain immunotoxin based on truncated diphtheria toxin has been described that can be expressed in CHO cells that have been mutated to diphtheria toxin resistance. After the two toxin glycosylation sites were removed, the bioactivity of the expressed immunotoxin was nearly equal to that of the chemically conjugated immunotoxin. This immunotoxin, A-dmDT390-sFv, contains diphtheria toxin to residue 390 at the N-terminus followed by VL and VH domains of antibody UCHT1 linked by a (G4S)3 spacer (sFv). Surprisingly, we now report that this immunotoxin is severely compromised in its binding affinity toward CD3+ cells as compared with the intact parental UCHT1 antibody, the UCHT1 Fab fragment or the engineered UCHT1 sFv domain alone. Binding was increased 7-fold by adding an additional identical sFv domain to the immunotoxin generating a divalent construct, A-dmDT390-bisFv (G4S). In vitro potency increased 10-fold over the chemically conjugated immunotoxin, UCHT1CRM9 and the monovalent A-dmDT390-sFv. The in vivo potency of the genetically engineered immunotoxins was assayed in the transgenic heterozygote mouse, tg
600, in which the T-cells express human CD3
as well as murine CD3
. T-cell depletion in the spleen and lymph node observed with the divalent construct was increased 9- and 34-fold, respectively, compared with the monovalent construct. The additional sFv domain appears partially to compensate for steric hindrance of immunotoxin binding due to the large N-terminal toxin domain.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G.-B. Kim, Z. Wang, Y. Y. Liu, S. Stavrou, A. Mathias, K.J. Goodwin, J. M. Thomas, and D. M. Neville A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin Protein Eng. Des. Sel., September 1, 2007; 20(9): 425 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J Knechtle Development of tolerogenic strategies in the clinic Phil Trans R Soc B, September 29, 2005; 360(1461): 1739 - 1746. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Liu, J. H. Woo, and D. M. Neville Jr. Overexpression of an Anti-CD3 Immunotoxin Increases Expression and Secretion of Molecular Chaperone BiP/Kar2p by Pichia pastoris Appl. Envir. Microbiol., September 1, 2005; 71(9): 5332 - 5340. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang, A. Mathias, S. Stavrou, and D.M. Neville Jr A new yeast display vector permitting free scFv amino termini can augment ligand binding affinities Protein Eng. Des. Sel., July 1, 2005; 18(7): 337 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Arnett, S. C. Harrison, and D. C. Wiley Crystal structure of a human CD3-{epsilon}/{delta} dimer in complex with a UCHT1 single-chain antibody fragment PNAS, November 16, 2004; 101(46): 16268 - 16273. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Szynol, J. J. de Soet, E. Sieben-van Tuyl, J. W. Bos, and L. G. Frenken Bactericidal Effects of a Fusion Protein of Llama Heavy-Chain Antibodies Coupled to Glucose Oxidase on Oral Bacteria Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3390 - 3395. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Woo, Y. Y. Liu, S. Stavrou, and D. M. Neville Jr. Increasing Secretion of a Bivalent Anti-T-Cell Immunotoxin by Pichia pastoris Appl. Envir. Microbiol., June 1, 2004; 70(6): 3370 - 3376. [Abstract] [Full Text] [PDF] |
||||




